Piramal Pharma Share Price
Sector: Biotechnology & Drugs
202.90 +1.95 (0.97%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
200.80
Today’s High
204.40
52 Week Low
145.55
52 Week High
307.85
202.83 +1.84 (0.92%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
200.93
Today’s High
204.46
52 Week Low
145.25
52 Week High
307.90
Key Metrics
- Market Cap (In Cr) 26863.5
- Beta -
- Div. Yield (%) 0.07
- P/B 3.27
- TTM P/E 325.72
- Peg Ratio -7.32
- Sector P/E 22.67
- D/E 0.01
- Open Price 203.95
- Prev Close 200.95
Piramal Pharma Analysis
Price Analysis
-
1 Week4.67%
-
3 Months-8.14%
-
6 Month-21.9%
-
YTD-24.51%
-
1 Year28.11%
Risk Meter
- 44% Low risk
- 44% Moderate risk
- 44% Balanced Risk
- 44% High risk
- 44% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 5
- 5
- 5
- 4
- Buy
- 4
- 4
- 4
- 2
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 9
- 9
- 9
- 6
Piramal Pharma News
Prashanth Tapse of Mehta Equities suggests THESE 4 stocks to buy in short term
4 min read . 06 Jun 2025How Trump's executive order on drug prices could hit Indian research companies
4 min read . 19 May 2025Piramal Pharma to see muted CDMO growth on US jitters; strong recovery in FY27
3 min read . 15 May 2025Piramal Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 9151.18
- Selling/ General/ Admin Expenses Total
- 2307.47
- Depreciation/ Amortization
- 816.34
- Other Operating Expenses Total
- 2167.23
- Total Operating Expense
- 8522.69
- Operating Income
- 628.49
- Net Income Before Taxes
- 414.64
- Net Income
- 91.13
- Diluted Normalized EPS
- 0.68
- Period
- 2025
- Total Assets
- 15677.59
- Total Liabilities
- 7552.12
- Total Equity
- 8125.47
- Tangible Book Valueper Share Common Eq
- 30.57
- Period
- 2025
- Cashfrom Operating Activities
- 892.3
- Cashfrom Investing Activities
- -477.46
- Cashfrom Financing Activities
- -440.83
- Net Changein Cash
- -36.87
- Period
- 2024
- Total Revenue
- 8171.16
- Selling/ General/ Admin Expenses Total
- 2634.67
- Depreciation/ Amortization
- 740.57
- Other Operating Expenses Total
- -50.92
- Total Operating Expense
- 6683.37
- Operating Income
- 1487.79
- Net Income Before Taxes
- 179.29
- Net Income
- 17.82
- Diluted Normalized EPS
- 0.46
- Period
- 2024
- Total Assets
- 15311.81
- Total Liabilities
- 7400.44
- Total Equity
- 7911.37
- Tangible Book Valueper Share Common Eq
- 27.38
- Period
- 2024
- Cashfrom Operating Activities
- 1004.54
- Cashfrom Investing Activities
- -434.01
- Cashfrom Financing Activities
- -422.36
- Net Changein Cash
- 165.96
- Period
- 2023
- Total Revenue
- 7081.55
- Selling/ General/ Admin Expenses Total
- 2416.27
- Depreciation/ Amortization
- 676.69
- Other Operating Expenses Total
- -159.77
- Total Operating Expense
- 5937.62
- Operating Income
- 1143.93
- Net Income Before Taxes
- -120.15
- Net Income
- -186.46
- Diluted Normalized EPS
- -1.49
- Period
- 2023
- Total Assets
- 14522.56
- Total Liabilities
- 7749.06
- Total Equity
- 6773.5
- Tangible Book Valueper Share Common Eq
- 19.12
- Period
- 2023
- Cashfrom Operating Activities
- 483.89
- Cashfrom Investing Activities
- -1338.78
- Cashfrom Financing Activities
- 817.79
- Net Changein Cash
- -31.95
- Period
- 2022
- Total Revenue
- 6559.1
- Selling/ General/ Admin Expenses Total
- 1997.5
- Depreciation/ Amortization
- 586.18
- Other Operating Expenses Total
- -77
- Total Operating Expense
- 5264.9
- Operating Income
- 1294.2
- Net Income Before Taxes
- 484.98
- Net Income
- 375.96
- Diluted Normalized EPS
- 3.21
- Period
- 2022
- Total Assets
- 12797.04
- Total Liabilities
- 6100.44
- Total Equity
- 6696.6
- Tangible Book Valueper Share Common Eq
- 19.44
- Period
- 2022
- Cashfrom Operating Activities
- 843.16
- Cashfrom Investing Activities
- -1812.1
- Cashfrom Financing Activities
- 794.19
- Net Changein Cash
- -176.79
- Period
- 2021
- Total Revenue
- 2938.81
- Selling/ General/ Admin Expenses Total
- 456.69
- Depreciation/ Amortization
- 143.64
- Other Operating Expenses Total
- -52.4
- Total Operating Expense
- 1844.83
- Operating Income
- 1093.98
- Net Income Before Taxes
- 686.78
- Net Income
- 571.5
- Diluted Normalized EPS
- 4.7
- Period
- 2021
- Total Assets
- 5756.67
- Total Liabilities
- 1656.05
- Total Equity
- 4100.62
- Tangible Book Valueper Share Common Eq
- 30.78
- Period
- 2021
- Cashfrom Operating Activities
- 34.72
- Cashfrom Investing Activities
- -4382.89
- Cashfrom Financing Activities
- 4494.16
- Net Changein Cash
- 145.99
- Period
- 2025-03-31
- Total Revenue
- 2754.07
- Selling/ General/ Admin Expenses Total
- 612.01
- Depreciation/ Amortization
- 242.76
- Other Operating Expenses Total
- 626.09
- Total Operating Expense
- 2435.84
- Operating Income
- 318.23
- Net Income Before Taxes
- 272.8
- Net Income
- 153.5
- Diluted Normalized EPS
- 1.16
- Period
- 2025-03-31
- Total Assets
- 15677.59
- Total Liabilities
- 7552.12
- Total Equity
- 8125.47
- Tangible Book Valueper Share Common Eq
- 30.57
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 892.3
- Cashfrom Investing Activities
- -477.46
- Cashfrom Financing Activities
- -440.83
- Net Changein Cash
- -36.87
- Period
- 2024-12-31
- Total Revenue
- 2204.22
- Selling/ General/ Admin Expenses Total
- 556.24
- Depreciation/ Amortization
- 196.81
- Other Operating Expenses Total
- 504.41
- Total Operating Expense
- 2063.29
- Operating Income
- 140.93
- Net Income Before Taxes
- 66.8
- Net Income
- 3.68
- Diluted Normalized EPS
- 0.03
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 2241.75
- Selling/ General/ Admin Expenses Total
- 559.53
- Depreciation/ Amortization
- 192.22
- Other Operating Expenses Total
- 544.14
- Total Operating Expense
- 2092.36
- Operating Income
- 149.39
- Net Income Before Taxes
- 120.12
- Net Income
- 22.59
- Diluted Normalized EPS
- 0.17
- Period
- 2024-09-30
- Total Assets
- 15241.74
- Total Liabilities
- 7334.57
- Total Equity
- 7907.17
- Tangible Book Valueper Share Common Eq
- 28.26
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 184.71
- Cashfrom Investing Activities
- -74.42
- Cashfrom Financing Activities
- -262.51
- Net Changein Cash
- -157.52
- Period
- 2024-06-30
- Total Revenue
- 1951.14
- Selling/ General/ Admin Expenses Total
- 579.69
- Depreciation/ Amortization
- 184.55
- Other Operating Expenses Total
- 492.59
- Total Operating Expense
- 1931.2
- Operating Income
- 19.94
- Net Income Before Taxes
- -45.08
- Net Income
- -88.64
- Diluted Normalized EPS
- -0.67
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2552.36
- Selling/ General/ Admin Expenses Total
- 526.05
- Depreciation/ Amortization
- 196.13
- Other Operating Expenses Total
- -26.38
- Total Operating Expense
- 1740.71
- Operating Income
- 811.65
- Net Income Before Taxes
- 227.48
- Net Income
- 101.27
- Diluted Normalized EPS
- 0.86
- Period
- 2024-03-31
- Total Assets
- 15311.81
- Total Liabilities
- 7400.44
- Total Equity
- 7911.37
- Tangible Book Valueper Share Common Eq
- 27.38
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1004.54
- Cashfrom Investing Activities
- -434.01
- Cashfrom Financing Activities
- -422.36
- Net Changein Cash
- 165.96
- Period
- 2023-12-31
- Total Revenue
- 1958.57
- Selling/ General/ Admin Expenses Total
- 523.78
- Depreciation/ Amortization
- 186.32
- Other Operating Expenses Total
- -61.51
- Total Operating Expense
- 1356.01
- Operating Income
- 602.56
- Net Income Before Taxes
- 19.36
- Net Income
- 10.11
- Diluted Normalized EPS
- 0.21
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Piramal Pharma Technical
Moving Average
SMA
- 5 Day194.9
- 10 Day197.33
- 20 Day201.72
- 50 Day208.33
- 100 Day210.95
- 300 Day226.94
Piramal Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- J B Chemicals And Pharmaceutical
- 1802.9
- 51.15
- 2.92
- 2029
- 1303
- 28065.37
- Wockhardt
- 1638.8
- -17.05
- -1.03
- 1870
- 578.6
- 26627.05
- Piramal Pharma
- 202.9
- 1.95
- 0.97
- 307.85
- 145.55
- 26863.5
- Syngene International
- 643.15
- -2.7
- -0.42
- 960
- 598.55
- 25925.08
- Eris Lifesciences
- 1679.6
- 60.65
- 3.75
- 1909.55
- 988.95
- 22825.66
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- J B Chemicals And Pharmaceutical
- 43.24
- 8.15
- 20.84
- 16.36
- Wockhardt
- -
- 6.4
- -9.24
- -11.98
- Piramal Pharma
- 296.99
- 3.28
- -
- -
- Syngene International
- 55.48
- 5.53
- 13.02
- 15.03
- Eris Lifesciences
- 63.07
- 7.77
- 18.25
- 20.85
Piramal Pharma Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-May-25
- Audited Results & Final Dividend
- 28-Jan-25
- Quarterly Results
- 23-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 30-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 24-May-23
- Audited Results
- 08-Feb-23
- Quarterly Results & Rights issue
- Meeting Date
- Announced on
- Purpose
- 23-Mar-25
- 19-Feb-25
- POM
- 26-Jul-24
- 11-Jun-24
- AGM
- 31-Jul-23
- 16-Jun-23
- AGM
- 22-Mar-23
- 20-Feb-23
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 14-May-25
- -
- -
- 0.14
- 10-May-24
- 12-Jul-24
- 12-Jul-24
- 0.11


- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 08-Feb-23
- 02-Aug-23
- 02-Aug-23
- 5:46
- 10
- 71
- Rights issue of equity shares of Rs. 10/- in the ratio of 5:46 @ premium of Rs. 71/-.